With GLP-1 drugs booming, many drugmakers are now working on new weight-loss treatments. A rundown of what is coming.
Recap by typeshit. Full story at News Nation on MSN.
TIKR points to retatrutide, due for filing in early 2027, and says a pending Seventh Circuit ruling on whether it counts as a biologic could decide 5 vs 12 years of exclusivity.
She lost 7 kilos in her first month, regained it during a month-long break, and now says she's eating more and gaining in week two back.
A shared report on doctors turning to GLP-1 medications for weight loss in some kids. Details are thin, so tap through for the full story.
The author, who holds Novo shares, cites Morgan Stanley's $190 billion obesity market forecast for 2035 and an NIH-funded mouse study on aging.
Nippard puts the two approved drugs on top for supervised weight loss and holds retatrutide at B-tier until it is approved.
Bloomberg traces how Amgen used genetic data from Iceland to guide its obesity drug research.
Loading…